Target Group Inc (CBDY)
0.0058
0.00 (0.00%)
USD |
OTCM |
Apr 23, 16:00
Target Group Free Cash Flow (Quarterly): 0.2729M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 0.2729M |
September 30, 2023 | -0.5758M |
June 30, 2023 | -0.1221M |
March 31, 2023 | -0.1868M |
December 31, 2022 | 0.0554M |
September 30, 2022 | 0.129M |
June 30, 2022 | -1.347M |
March 31, 2022 | 0.1477M |
December 31, 2021 | 0.6119M |
September 30, 2021 | -0.2362M |
June 30, 2021 | 0.0077M |
March 31, 2021 | -0.2832M |
December 31, 2020 | -0.2132M |
September 30, 2020 | -0.3264M |
June 30, 2020 | -0.0661M |
March 31, 2020 | -0.87M |
December 31, 2019 | -0.2625M |
September 30, 2019 | -1.895M |
June 30, 2019 | -4.065M |
March 31, 2019 | -3.112M |
Date | Value |
---|---|
December 31, 2018 | -1.312M |
September 30, 2018 | -1.081M |
June 30, 2018 | -0.0554M |
March 31, 2018 | -0.055M |
December 31, 2017 | -0.0567M |
September 30, 2017 | -0.0617M |
June 30, 2017 | -0.0729M |
March 31, 2017 | -0.0709M |
December 31, 2016 | -0.008M |
September 30, 2016 | -0.1589M |
June 30, 2016 | -0.1437M |
March 31, 2016 | -0.1104M |
December 31, 2015 | -0.0644M |
September 30, 2015 | -0.0294M |
June 30, 2015 | -0.0436M |
March 31, 2015 | -0.0551M |
December 31, 2014 | -0.035M |
September 30, 2014 | -0.0024M |
June 30, 2014 | 0.00 |
March 31, 2014 | 0.00 |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-4.065M
Minimum
Jun 2019
0.6119M
Maximum
Dec 2021
-0.4855M
Average
-0.2132M
Median
Dec 2020
Free Cash Flow (Quarterly) Benchmarks
Acasti Pharma Inc | -1.892M |
Aurinia Pharmaceuticals Inc | 14.25M |
Edesa Biotech Inc | -1.406M |
Lexaria Bioscience Corp | -0.6766M |
Xenon Pharmaceuticals Inc | -35.54M |